2seventy Bio:U.S. revenue for Abecma ‘may be’ less than $470-$570M prior view

Revenue and impact to 2seventy: Based on an anticipated decline in Abecma sales in the third quarter, “we believe full-year 2023 U.S. revenue for Abecma could be lower than the $470-$570M range previously projected. 2seventy continues to expect Abecma to remain profitable this year and contribute significantly toward our cash runway into at least 2026 and remains confident in Abecma’s long-term commercial potential. Upcoming Milestones: The December 16, 2023 PDUFA date for potential label expansion based on the KarMMa-3 data in adult patients with triple-class exposed relapsed or refractory multiple myeloma and the planned initiation of the KarMMa-9 study in patients with newly diagnosed multiple myeloma with sub-optimal response post-ASCT later this year provide both short- and medium-term grounds for continued optimism in the commercial potential of… ”